- Authors: Kim, H., Frederick, D. T., Levesque, M. P., Cooper, Z. A., Feng, Y., Krepler, C., Brill, L., Samuels, Y., Hayward, N. K., Perlina, A., Piris, A., Zhang, T., Halaban, R., Herlyn, M. M., Brown, K. M., Wargo, J. A., Dummer, R., Flaherty, K. T., Ronai, Z. A.
- Year: 2015
- Journal: Cell Rep 11 1458-73
- Applications: in vitro / DNA, siRNA / jetPRIME
- Cell types:
- Name: A375
Description: Human skin melanoma cells
Known as: A-375
- Name: Lu1205
Description: Human melanoma cells
Known as: 1205lu
- Name: A375
Despite the remarkable clinical response of melanoma harboring BRAF mutations to BRAF inhibitors (BRAFi), most tumors become resistant. Here, we identified the downregulation of the ubiquitin ligase RNF125 in BRAFi-resistant melanomas and demonstrated its role in intrinsic and adaptive resistance to BRAFi in cultures as well as its association with resistance in tumor specimens. Sox10/MITF expression correlated with and contributed to RNF125 transcription. Reduced RNF125 was associated with elevated expression of receptor tyrosine kinases (RTKs), including EGFR. Notably, RNF125 altered RTK expression through JAK1, which we identified as an RNF125 substrate. RNF125 bound to and ubiquitinated JAK1, prompting its degradation and suppressing RTK expression. Inhibition of JAK1 and EGFR signaling overcame BRAFi resistance in melanoma with reduced RNF125 expression, as shown in culture and in in vivo xenografts. Our findings suggest that combination therapies targeting both JAK1 and EGFR could be effective against BRAFi-resistant tumors with de novo low RNF125 expression.